206 related articles for article (PubMed ID: 34991674)
1. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
Gu C; Wang Y; Zhang L; Qiao L; Sun S; Shao M; Tang X; Ding P; Tang C; Cao Y; Zhou Y; Guo M; Wei R; Li N; Xiao Y; Duan J; Yang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):11. PubMed ID: 34991674
[TBL] [Abstract][Full Text] [Related]
2. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
Xiang RF; Wang Y; Zhang N; Xu WB; Cao Y; Tong J; Li JM; Wu YL; Yan H
Cell Death Dis; 2017 May; 8(5):e2776. PubMed ID: 28492559
[TBL] [Abstract][Full Text] [Related]
3. Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.
Huang H; Cao Y; Wei W; Liu W; Lu SY; Chen YB; Wang Y; Yan H; Wu YL
PLoS One; 2013; 8(6):e66130. PubMed ID: 23762475
[TBL] [Abstract][Full Text] [Related]
4. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
5. Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
Yang L; Zhou F; Zhuang Y; Liu Y; Xu L; Zhao H; Xiang Y; Dai X; Liu Z; Huang X; Wang L; Zhao C
Br J Cancer; 2021 Feb; 124(3):645-657. PubMed ID: 33122847
[TBL] [Abstract][Full Text] [Related]
6. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
[TBL] [Abstract][Full Text] [Related]
7. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
8. BF211, a derivative of bufalin, enhances the cytocidal effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway.
Wu XY; Tian F; Su MH; Wu M; Huang Y; Hu LH; Jin L; Zhu XJ
Int Immunopharmacol; 2018 Nov; 64():24-32. PubMed ID: 30145467
[TBL] [Abstract][Full Text] [Related]
9. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
11. Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na
Lan YL; Wang X; Lou JC; Xing JS; Yu ZL; Wang H; Zou S; Ma X; Zhang B
Biomed Pharmacother; 2018 Jul; 103():204-215. PubMed ID: 29653366
[TBL] [Abstract][Full Text] [Related]
12. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson ID; Lin YT; Lam C; Shao H; Tharp KM; Hale M; Kasap C; Mariano MC; Kishishita A; Patiño Escobar B; Mandal K; Steri V; Wang D; Phojanakong P; Tuomivaara ST; Hann B; Driessen C; Van Ness B; Gestwicki JE; Wiita AP
Cell Chem Biol; 2022 Aug; 29(8):1288-1302.e7. PubMed ID: 35853457
[TBL] [Abstract][Full Text] [Related]
13. Bufalin, a Traditional Chinese Medicine Compound, Prevents Tumor Formation in Two Murine Models of Colorectal Cancer.
Sun X; Ng TTH; Sham KWY; Zhang L; Chan MTV; Wu WKK; Cheng CHK
Cancer Prev Res (Phila); 2019 Oct; 12(10):653-666. PubMed ID: 31431500
[TBL] [Abstract][Full Text] [Related]
14. Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and in vitro Studies.
Shi W; Qi L; You XB; Chen YC; Xu YL; Yu WB; Huang MY; Zhao H; Lu JJ
Curr Cancer Drug Targets; 2022; 22(2):142-152. PubMed ID: 35034596
[TBL] [Abstract][Full Text] [Related]
15. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.
Wang H; Xiao X; Li Z; Luo S; Hu L; Yi H; Xiang R; Zhu Y; Wang Y; Zhu L; Xiao L; Dai C; Aziz A; Yuan L; Cui Y; Li R; Gong F; Liu X; Liang L; Peng H; Zhou H; Liu J
Cancer Lett; 2022 Jul; 537():215647. PubMed ID: 35306105
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
17. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.
Ge M; Qiao Z; Kong Y; Liang H; Sun Y; Lu H; Xu Z; Liu H
Br J Cancer; 2021 Feb; 124(4):770-776. PubMed ID: 33250513
[TBL] [Abstract][Full Text] [Related]
18. Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
Yu Z; Wei X; Liu L; Sun H; Fang T; Wang L; Li Y; Sui W; Wang K; He Y; Zhao Y; Huang W; An G; Meng F; Huang C; Yu T; Anderson KC; Cheng T; Qiu L; Hao M
EBioMedicine; 2022 Apr; 78():103950. PubMed ID: 35344764
[TBL] [Abstract][Full Text] [Related]
19. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
Chroma K; Skrott Z; Gursky J; Bacovsky J; Moudry P; Buchtova T; Mistrik M; Bartek J
Cell Death Dis; 2022 Mar; 13(3):203. PubMed ID: 35246527
[TBL] [Abstract][Full Text] [Related]
20. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
